Prothena Corporation plc Logo

Email this page: News Release

Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson's Disease

For security reasons, registration is required before you can use this feature.
* Indicates required field